Becton, Dickinson and Company Stock Outlook: Is Wall Street Bullish or Bearish?

Becton, Dickinson and Company Stock Outlook: Is Wall Street Bullish or Bearish?

Becton, Dickinson and Company (BDX) develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products. Valued at $59.4 billion by market cap, the company offers solutions that help advance medical research and genomics, enhance the diagnosis of infectious disease and cancer, improve medication management, and promote infection prevention.

Shares of this global medical technology giant have outperformed the broader market over the past year. BDX has gained 43.5% over this time frame, while the broader S&P 500 Index ($SPX) has rallied nearly 10%. In 2026, BDX stock is up 41.2%, surpassing the SPX’s 7.2% rise on a YTD basis. 

More Top Stocks Daily: Go behind Wall Street’s hottest headlines with Barchart’s Active Investor newsletter.

 

Zooming in further, BDX’s outperformance is also apparent compared to the iShares U.S. Medical Devices ETF (IHI). The exchange-traded fund has declined about 7.7% over the past year. Moreover, the stock’s double-digit returns on a YTD basis outshine the ETF’s 8.4% losses over the same time frame.

www.barchart.com

BDX’s recent momentum and outperformance have been driven by solid execution across its core med-tech portfolio, highlighted by robust demand for drug delivery devices, connected medication management systems (such as Pyxis and Alaris integrations), and automation solutions like the Vmax 160 pharmacy robot. Investors have also responded favorably to the company’s resilient margin expansion, disciplined cost controls, and accelerating cash generation, evidenced by double-digit profit beats and significant growth in free cash flow. Additionally, strategic pipeline catalysts including positive clinical trial milestones in advanced tissue regeneration and vascular devices, alongside a major U.S. manufacturing expansion agreement providing long-term tariff relief, have reinforced confidence in the company's durable growth trajectory.

On Nov. 5, BDX shares closed up more than 2% after reporting its Q4 results. Its adjusted EPS of $4.15 beat Wall Street expectations of $4.06. The company’s revenue was $5.3 billion, topping Wall Street forecasts of $5.1 billion. BDX expects full-year adjusted EPS in the range of $13.10 to $13.30.

For fiscal 2027, ending in September 2027, analysts expect BDX’s EPS to grow 4% to $13.21 on a diluted basis. The company’s earnings surprise history is impressive. It beat the consensus estimate in each of the last four quarters.

Among the 17 analysts covering BDX stock, the consensus is a “Moderate Buy.” That’s based on nine “Strong Buy” ratings, seven “Holds,” and one “Strong Sell.”

www.barchart.com

This configuration is more bullish than a month ago, with six analysts suggesting a “Strong Buy.”

On Nov. 10, Barclays PLC (BCS) analyst Christopher Pasquale kept an “Underweight” rating on BDX and raised the price target to $195.

The mean price target of $220.56 represents a 2.4% premium to BDX’s current price levels. The Street-high price target of $242 suggests an upside potential of 12.3%.


On the date of publication, Neha Panjwani did not directly have a position in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.

 

More news from Barchart

‘I Would Be Honored to Answer These Calls and Return as CEO,’ Jensen Huang Says as Employees, Fellow Tech Leaders Rally Behind the Nvidia Founder Billionaire Charlie Munger Called Robinhood ‘A Gambling Parlor Masquerading As a Respectable Business’ and Now They Hold 70 Million Trump Accounts A Strong Q3 Puts Nvidia (NVDA) Stock on Track for a Quick 194% Options Payout As Netflix Stock Hovers Near Its 52-Week Low, Analyst Sentiment Remains Mixed. Here's Why.